Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prevalence and Characteristics of Symptomatic Uncomplicated Diverticular Disease Among Asian Patients With Unexplained Abdominal Symptoms.
Jono T, Kasai Y, Kessoku T, Ogata T, Tanaka K, Yoshihara T, Misawa N, Kato S, Higurashi T, Hosono K, Yoneda M, Seita K, Kato T, Sakai E, Kurihashi T, Nakatogawa M, Oyamada S, Futagami S, Gwee KA, Nakajima A. Jono T, et al. Among authors: nakatogawa m. J Neurogastroenterol Motil. 2024 Jan 30;30(1):87-96. doi: 10.5056/jnm22162. Epub 2023 Nov 28. J Neurogastroenterol Motil. 2024. PMID: 38012092 Free PMC article.
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol.
Yoshihara T, Kessoku T, Takatsu T, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Iwaki M, Kurihashi T, Nakatogawa M, Yamamoto K, Terada I, Tanaka Y, Nakajima A. Yoshihara T, et al. Among authors: nakatogawa m. Contemp Clin Trials Commun. 2022 Oct 28;30:101019. doi: 10.1016/j.conctc.2022.101019. eCollection 2022 Dec. Contemp Clin Trials Commun. 2022. PMID: 36387985 Free PMC article.
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation.
Yamamoto A, Kessoku T, Tanaka K, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Kobayashi T, Yoshihara T, Misawa N, Ohkuma K, Fuyuki A, Higurashi T, Hosono K, Yoneda M, Iwasaki T, Kurihashi T, Nakatogawa M, Suzuki A, Taguri M, Oyamada S, Ariyoshi K, Kobayashi N, Ichikawa Y, Nakajima A. Yamamoto A, et al. Among authors: nakatogawa m. Contemp Clin Trials Commun. 2022 Jun 27;28:100958. doi: 10.1016/j.conctc.2022.100958. eCollection 2022 Aug. Contemp Clin Trials Commun. 2022. PMID: 35812817 Free PMC article.
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
Tanaka K, Kessoku T, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Kobayashi T, Yoshihara T, Misawa N, Kato T, Arimoto J, Fuyuki A, Sakai E, Higurashi T, Chiba H, Hosono K, Yoneda M, Iwasaki T, Kurihashi T, Nakatogawa M, Suzuki A, Taguri M, Oyamada S, Ariyoshi K, Kobayashi N, Ichikawa Y, Nakajima A. Tanaka K, et al. Among authors: nakatogawa m. BMJ Open. 2022 May 30;12(5):e060704. doi: 10.1136/bmjopen-2021-060704. BMJ Open. 2022. PMID: 35636802 Free PMC article. Clinical Trial.